News
& Events
News
& Events

News
& Events

Inversago Pharma will participate to the 11th Annual SVB Leerink Global Healthcare Conference

Montreal, Canada – February 3, 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today that François Ravenelle, PhD, CEO, will participate to the private company days of the 11th Annual SVB Leerink Global Healthcare Conference. Conference held virtually, Feb.14-18, 2022 Private Company Days:  Monday, Feb. 14 and Tuesday, Feb. 15. SVB […]

Read more

Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update

Company has completed the Phase 1 Clinical Trial for its INV-202 molecule Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development Metabolic disorders are a global epidemic 1 Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the […]

Read more

Inversago Pharma Appoints Karine Lalonde, MSc to the position of Vice-President, Clinical Operations

MONTREAL (CANADA) – January 10, 2022 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Karine Lalonde, MSc as Vice-President, Clinical Operations, effective immediately. With 20 years of experience in clinical research operations, she brings to Inversago’s drug development program proven abilities in seamless clinical trial […]

Read more

Inversago Pharma Appoints Michael D. Harvey, PhD to the position of Chief Development Officer

MONTREAL (CANADA) – October 25, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Chief Development Officer (CDO), effective immediately. With over 20 years of experience and a proven track record in the pharmaceutical and biotechnology industry, Dr. Harvey will […]

Read more